Integrated Pharmaceuticals Inc - Current report filing (8-K)
01 August 2008 - 9:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C.
20549
FORM 8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF
REPORT
(DATE OF
EARLIEST EVENT REPORTED)
July
30, 2008
INTEGRATED PHARMACEUTICALS,
INC
(EXACT
NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
COMMISSION
FILE NUMBER
000-50960
Integrated
Pharmaceuticals, Inc.
(Exact
name of small business issuer in its charter)
Idaho
|
04-3413196
|
(State
or other jurisdiction of incorporation or
organization)
|
(I.R.S. Employer Identification
No.)
|
|
|
310 Authority
Drive
Fitchburg, MA
01420
(Address
of principal executive offices) (Zip Code)
(978) 696-0020
(Issuer
’
s telephone
number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM 4.01.
Change in Registrant’s Certifying Accountant
Engagement
of New Independent Public Accountant
On
July 30, 2008, we engaged Carlin Charron & Rosen LLP (“
CCR
”) to serve as our
independent public accountant. During our two most recent fiscal
years (the 2006 and 2007 calendar years) and during 2008, we have not consulted
CCR with respect to:
(i)
|
The
application of accounting principles to a specified transaction, either
completed or proposed;
|
(ii)
|
the
type of audit opinion that might be rendered on our financial
statements;
|
(iii)
|
Any
matter that was the subject of a disagreement (as defined in paragraph
304(a)(1)(iv) of SEC regulation S-K and the
related instructions);
or
|
(iv)
|
Any
matter that was a reportable event (as described in paragraph
304(a)(1)(v)) of SEC regulation S-K and the
related instructions).
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
INTEGRATED PHARMACEUTICALS,
INC.
|
|
|
|
DATE: July 30,
2008
|
By:
|
/s/
Peter
Featherston
|
|
Peter
Featherston
|
|
President
and Chief Executive Officer
|
Integrated Pharmaceuticals (CE) (USOTC:INTP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Integrated Pharmaceuticals (CE) (USOTC:INTP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Integrated Pharmaceuticals Inc (CE) (OTCMarkets): 0 Nachrichtenartikel
Weitere Integrated Pharmaceuticals Inc News-Artikel